Waltham, MA, United States of America

David L Wensel

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2019-2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovator Spotlight: David L. Wensel and His Contributions to HIV Research

Introduction: David L. Wensel, an accomplished inventor based in Waltham, MA, is recognized for his innovative work in the field of HIV treatment. With a total of two patents to his name, Wensel has made significant strides in developing therapeutic proteins that target the complexities of HIV fusion.

Latest Patents: Wensel's most recent inventions revolve around polypeptides aimed at HIV fusion. These inventions are particularly focused on polypeptides that incorporate a CD4 binding moiety, a gp41 binding moiety, and a HIV fusion peptide inhibitor moiety. More specifically, his patents describe polypeptides that utilize a fibronectin-based scaffold domain protein that binds to CD4, another fibronectin-based scaffold domain protein that targets the N17 domain of gp41, as well as the HIV fusion peptide inhibitor. The therapeutic applications for these innovative proteins could play a crucial role in advancing HIV treatments.

Career Highlights: As part of his professional journey, David Wensel is associated with ViiV Healthcare UK Limited, where he collaborates with a team dedicated to pioneering advancements in HIV therapies. His inventions not only exemplify his deep commitment to medical research but also highlight his ability to merge innovation with practical solutions for pressing health concerns.

Collaborations: Throughout his career, Wensel has worked closely with notable colleagues such as Mark R. Krystal and Jonathan Davis. Their collaborative efforts reinforce the importance of teamwork in innovation, particularly in complex fields such as virology and therapeutic development.

Conclusion: David L. Wensel stands out as a significant inventor in the realm of HIV treatment. His contributions through innovative polypeptides showcase the potential for new therapeutic approaches to combat this challenging virus. As Wensel continues his work at ViiV Healthcare UK Limited, the medical community eagerly anticipates further advancements that may emerge from his inventive mind.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…